Critical Care Group-Portex Unit, Institute of Child Health, University College London, London, UK.
Pediatr Crit Care Med. 2013 Jul;14(6):e289-97. doi: 10.1097/PCC.0b013e31828a8624.
Our objectives were to describe the prevalence of arrhythmia and conduction abnormalities before critical care intubation and to test the hypothesis that atropine had no effect on their prevalence during intubation.
Prospective, observational study.
PICU and pediatric/neonatal intensive care transport.
All children of age less than 8 years intubated September 2007-2009. Subgroups of intubations with and without atropine were analyzed.
None.
A total of 414 intubations were performed in the study period of which 327 were available for analysis (79%). Five children (1.5%) had arrhythmias prior to intubation and were excluded from the atropine analysis. Atropine was used in 47% (152/322) of intubations and resulted in significant acceleration of heart rate without provoking ventricular arrhythmias. New arrhythmias during intubation were related to bradycardia and were less common with atropine use (odds ratio, 0.14 [95% CI, 0.06-0.35], p < 0.001). The most common new arrhythmia was junctional rhythm. Acute bundle branch block was observed during three intubations; one Mobitz type 2 rhythm and five ventricular escape rhythms occurred in the no-atropine group (n = 170). Only one ventricular escape rhythm occurred in the atropine group (n = 152) in a child with an abnormal heart. One child died during intubation who had not received atropine.
Atropine significantly reduced the prevalence of new arrhythmias during intubation particularly for children over 1 month of age, did not convert sinus tachycardia to ventricular tachycardia or fibrillation, and may contribute to the safety of intubation.
描述危重症患者插管前心律失常和传导异常的发生率,并验证在插管期间应用阿托品对其发生率无影响的假设。
前瞻性观察性研究。
儿科重症监护病房(PICU)和儿科/新生儿重症监护转运。
2007 年 9 月至 2009 年期间所有年龄小于 8 岁的插管患儿。分析了使用和未使用阿托品的插管亚组。
无。
在研究期间共进行了 414 次插管,其中 327 次可用于分析(79%)。5 例(1.5%)患儿在插管前即存在心律失常,因此被排除在阿托品分析之外。在 47%(152/322)的插管中使用了阿托品,结果使心率显著加快,而未诱发室性心律失常。插管期间新发心律失常与心动过缓有关,使用阿托品时较少发生(比值比,0.14 [95%CI,0.06-0.35],p < 0.001)。最常见的新发心律失常为交界性节律。3 次插管中观察到急性束支传导阻滞;在未使用阿托品的 170 例患儿中,1 例发生莫氏 2 型节律,5 例发生心室逸搏节律;在使用阿托品的 152 例患儿中仅发生 1 例心室逸搏节律,发生于 1 例心脏异常患儿。1 例未使用阿托品的患儿在插管过程中死亡。
阿托品显著降低了插管期间新发心律失常的发生率,尤其是对于 1 个月以上的患儿,不会将窦性心动过速转化为室性心动过速或颤动,可能有助于提高插管的安全性。